Dr. Reichstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
345 23rd Ave N
Nashville, TN 37203Phone+1 615-983-6000Fax+1 615-983-6010
Education & Training
Icahn School of Medicine at Mount SinaiClass of 2006
Certifications & Licensure
KY State Medical License 2014 - 2025
TN State Medical License 2014 - 2025
WI State Medical License 2012 - 2015
PA State Medical License 2009 - 2014- American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.Susan B Bressler, Abhijit Barve, Prasanna C Ganapathi, Katrin Beckmann, Rajendra S Apte
JAMA Ophthalmology. 2024-10-01 - 1 citationsSUSTAINED BIWEEKLY AFLIBERCEPT FOR REFRACTORY NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Prospective TRISTAR Study.Eric W Schneider, Mridul K Thomas, Franco M Recchia, David A Reichstein, Carl C Awh
Retina. 2023-05-01 - 7 citationsTreatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.David Reichstein, Anderson Brock, Caressa Lietman, Meredith McKean
Current Opinion in Ophthalmology. 2022-11-01
Press Mentions
Eye Physics (EP) Plaques for Uveal Melanoma: Initial 12- and 24-Month Results in a Private Practice Setting Performed by a Young SurgeonJuly 26th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
